

# CENTER FOR DRUG EVALUATION AND RESEARCH

## Approval Package for:

### ***APPLICATION NUMBER:***

**022335Orig1s000**

***Trade Name:*** TECHNEGAS

***Generic or Proper Name:*** kit for the preparation of technetium Tc 99m-labeled carbon inhalation aerosol

***Sponsor:*** Cyclomedica Australia Pty Ltd.

***Approval Date:*** September 29, 2023

***Indication:*** TECHNEGAS, when used with sodium pertechnetate Tc 99m in the Technegas Plus System, provides technetium Tc 99m-labeled carbon inhalation aerosol (Technegas Aerosol), for use in adults and pediatric patients aged 6 years and older for:

- visualization of pulmonary ventilation
- evaluation of pulmonary embolism when paired with perfusion imaging

# CENTER FOR DRUG EVALUATION AND RESEARCH

## 022335Orig1s000

### CONTENTS

#### Reviews / Information Included in this NDA Review.

<b>Approval Letter</b>	<b>X</b>
<b>Other Action Letters</b>	<b>X</b>
<b>Labeling</b>	<b>X</b>
<b>REMS</b>	
<b>Officer/Employee List</b>	<b>X</b>
<b>Multidiscipline Review(s)</b> <ul style="list-style-type: none"><li>• <b>Summary Review</b></li><li>• <b>Clinical</b></li><li>• <b>Non-Clinical</b></li><li>• <b>Statistical</b></li><li>• <b>Clinical Pharmacology</b></li></ul>	<b>X</b>
<b>Product Quality Review(s)</b>	<b>X</b>
<b>Clinical Microbiology / Virology Review(s)</b>	
<b>Other Reviews</b>	<b>X</b>
<b>Risk Assessment and Risk Mitigation Review(s)</b>	<b>X</b>
<b>Proprietary Name Review(s)</b>	<b>X</b>
<b>Administrative/Correspondence Document(s)</b>	

**CENTER FOR DRUG EVALUATION AND  
RESEARCH**

*APPLICATION NUMBER:*

**022335Orig1s000**

**APPROVAL LETTER**

NDA 022335

**NDA APPROVAL**

Cyclomedica Australia Pty Ltd.  
c/o Certus International  
Attention: Karen Wolfe-Kerker,  
Vice President, Regulatory Affairs  
9 Cedarwood Dr., Suite 8  
Bedford, NH 03110

Dear Karen Wolfe-Kerker:

Please refer to your new drug application (NDA) dated and received on March 26, 2020, and your amendments submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA) for TECHNEGAS (kit for the preparation of technetium Tc 99m-labeled carbon inhalation aerosol).

We acknowledge receipt of your amendment dated March 29, 2023, which constituted a complete response to our June 25, 2021, action letter.

This NDA provides for the use of TECHNEGAS, when used with sodium pertechnetate Tc 99m in the Technegas Plus System, to prepare technetium Tc 99m-labeled carbon inhalation aerosol (Technegas Aerosol), for use in adults and pediatric patients aged 6 years and older for:

- visualization of pulmonary ventilation
- evaluation of pulmonary embolism when paired with perfusion imaging.

### **APPROVAL & LABELING**

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

### **CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.<sup>1</sup> Content of labeling must be identical to the enclosed labeling as well as annual reportable changes not included in the enclosed labeling. Information on

---

<sup>1</sup> <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.<sup>2</sup>

The SPL will be accessible via publicly available labeling repositories.

### **CARTON AND CONTAINER LABELING**

We acknowledge your September 19, 2023, submission containing final printed carton and container labeling.

### **DATING PERIOD**

Based on the stability data submitted to date, the expiry dating period for TECHNEGAS (kit for the preparation of of technetium Tc 99m-labeled carbon inhalation aerosol) shall be 24 months from the date of manufacture when stored at 15°-30°C (59° –86°F).

The maximum use period for the Technegas Plus System is 500 burn cycles or one year, whichever is sooner. Prior to further use, the Technegas Plus System must be recertified by Cyclomedica according to your quality system, which includes correcting any aspect of the Technegas Plus System that may affect Technegas Aerosol quality and optimum performance of the Technegas Plus System.

### **REQUIRED PEDIATRIC ASSESSMENTS**

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

We are waiving the pediatric study requirement from birth to less than 6 years of age because necessary studies are impossible or highly impracticable.

### **PROMOTIONAL MATERIALS**

You may request advisory comments on proposed introductory advertising and promotional labeling. For information about submitting promotional materials, see the final guidance for industry *Providing Regulatory Submissions in Electronic and Non-Electronic Format—Promotional Labeling and Advertising Materials for Human Prescription Drugs*.<sup>3</sup>

---

<sup>2</sup> We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

<sup>3</sup> For the most recent version of a guidance, check the FDA guidance web page at <https://www.fda.gov/media/128163/download>.

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the Prescribing Information, at the time of initial dissemination or publication, accompanied by a Form FDA 2253. Form FDA 2253 is available at FDA.gov.<sup>4</sup> Information and Instructions for completing the form can be found at FDA.gov.<sup>5</sup>

## **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

Your product is a Part 3 combination product (21 CFR 3.2(e)); therefore, you must also comply with postmarketing safety reporting requirements for an approved combination product (21 CFR 4, Subpart B). Additional information on combination product postmarketing safety reporting is available at FDA.gov.<sup>6</sup>

If you have any questions, call Modupe Fagbami, Regulatory Project Manager, at 301-796-1348.

Sincerely,

*{See appended electronic signature page}*

Libero Marzella, M.D., Ph.D.  
Director  
Division of Imaging and Radiation Medicine  
Office of Specialty Medicine  
Office of New Drugs  
Center for Drug Evaluation and Research

### ENCLOSURES:

- Content of Labeling
  - Prescribing Information
  - User Manual
- Carton and Container Labeling

---

<sup>4</sup> <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>

<sup>5</sup> <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>

<sup>6</sup> <https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products>

-----  
**This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.**  
-----

/s/  
-----

LIBERO L MARZELLA  
09/29/2023 10:26:18 AM